CRNX vs NVS
Crinetics Pharmaceuticals, Inc. vs Novartis AG — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
65
Buy
VS
| Metric | CRNX | NVS |
|---|
| AI Score |
65
|
75
|
| Price |
$84.35
|
$154.64
|
| P/E Ratio |
-16.70×
|
23.55×
|
| ROE |
-46.9%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
74.3%
|
| Debt / Equity |
0.00×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
89.2
|
57.7
|
| Beta |
0.1302
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus NVS.
NVS leads by 10 points.
NVS scores 75/100 (Buy) versus CRNX at 65/100 (Buy).
CRNX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical